bs_bs_banner
Therapeutic Apheresis and Dialysis 2014; 18(Supplement 2):1 doi: 10.1111/1744-9987.12231 © 2014 The Author Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis
Preface Hyperphosphatemia is a prognostic factor for morbidity and mortality in chronic kidney disease. Bixalomer (Kiklin capsules), which originated from Ilypsa (a subsidiary of Amgen), is a non-absorbable polymer that decreases serum phosphate levels by binding phosphate in the gastrointestinal tract. Bixalomer was developed by Astellas Pharma Inc. and was approved in March 2012 by the Japanese Ministry of Health, Labour and Welfare. This agent caused less constipation and abdominal distension than sevelamer hydrochloride in clinical trials, possibly because bixalomer absorbs less water, and showed less swelling, lower viscosity, and higher fluidity than sevelamer hydrochloride when mixed with water. The 58th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) was held in the International Congress Center, Sunpalace, Marinemesse, and Kokusai Center in Fukuoka from June 20 to 23, 2013, and was organized by Congress Chairman Hideki Hirakata, MD, PhD (Japanese Red Cross, Fukuoka Hospital). In this meeting, he programmed an Invited Lecture by Makoto Kuro-o (University of Texas Southwestern Medical Center at Dallas) entitled “A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease.” He also stressed the importance of phosphate control for preventing cardiovascular disease in chronic kidney disease (CKD) patients by organizing the CKD-MBD International Symposium on Mineral Bone Disorder (MBD) and Prognosis, with foreign guests, including Kamyar Kalantar-Zadeh, Ravi Thadhani, Tilman B. Drueke, and Gérard M. London.
This meeting was the first major opportunity for researchers and clinicians involved in performing dialysis to report clinical one-year experiences and discuss the characteristics of this drug in clinical use. This supplement of Therapeutic Apheresis and Dialysis contains five papers that were presented at that meeting. The experiences described vary from a double-blind control to a switch study to a retrospective observational study, with outcomes provided in terms of serum phosphate levels, correction of acidosis, serum concentration of high-density lipoprotein cholesterol, and gastrointestinal symptom rating scale. This supplement represents a veritable trove of information on bixalomer for clinicians in the dialysis field, and provides valuable information for the treatment of CKD-MBD. I do hope that this supplement will provide all healthcare professionals who are engaged in the management of CKD with an advanced knowledge of Bixalomer. I also hope that they will thereby contribute to the improvement of the quality of medical care by providing relief to patients’ suffering and decreasing the burden on patients. Takashi Akiba, MD, PhD Department of Blood Purification, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan Conflict of Interests: Research Support: Chugai Pharmaceutical Co., Toray Industries, Torii Pharmaceutical Co. and Otsuka Pharmaceutical Co. Honoraria: Kyowa Hakko Kirin Co., Astellas Pharma, Asahi Kasei Pharma and NIPRO.
1
Therapeutic Apheresis and Dialysis 2014; 18(Supplement 2):1 doi: 10.1111/1744-9987.12231 © 2014 The Author Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis
Preface Hyperphosphatemia is a prognostic factor for morbidity and mortality in chronic kidney disease. Bixalomer (Kiklin capsules), which originated from Ilypsa (a subsidiary of Amgen), is a non-absorbable polymer that decreases serum phosphate levels by binding phosphate in the gastrointestinal tract. Bixalomer was developed by Astellas Pharma Inc. and was approved in March 2012 by the Japanese Ministry of Health, Labour and Welfare. This agent caused less constipation and abdominal distension than sevelamer hydrochloride in clinical trials, possibly because bixalomer absorbs less water, and showed less swelling, lower viscosity, and higher fluidity than sevelamer hydrochloride when mixed with water. The 58th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) was held in the International Congress Center, Sunpalace, Marinemesse, and Kokusai Center in Fukuoka from June 20 to 23, 2013, and was organized by Congress Chairman Hideki Hirakata, MD, PhD (Japanese Red Cross, Fukuoka Hospital). In this meeting, he programmed an Invited Lecture by Makoto Kuro-o (University of Texas Southwestern Medical Center at Dallas) entitled “A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease.” He also stressed the importance of phosphate control for preventing cardiovascular disease in chronic kidney disease (CKD) patients by organizing the CKD-MBD International Symposium on Mineral Bone Disorder (MBD) and Prognosis, with foreign guests, including Kamyar Kalantar-Zadeh, Ravi Thadhani, Tilman B. Drueke, and Gérard M. London.
This meeting was the first major opportunity for researchers and clinicians involved in performing dialysis to report clinical one-year experiences and discuss the characteristics of this drug in clinical use. This supplement of Therapeutic Apheresis and Dialysis contains five papers that were presented at that meeting. The experiences described vary from a double-blind control to a switch study to a retrospective observational study, with outcomes provided in terms of serum phosphate levels, correction of acidosis, serum concentration of high-density lipoprotein cholesterol, and gastrointestinal symptom rating scale. This supplement represents a veritable trove of information on bixalomer for clinicians in the dialysis field, and provides valuable information for the treatment of CKD-MBD. I do hope that this supplement will provide all healthcare professionals who are engaged in the management of CKD with an advanced knowledge of Bixalomer. I also hope that they will thereby contribute to the improvement of the quality of medical care by providing relief to patients’ suffering and decreasing the burden on patients. Takashi Akiba, MD, PhD Department of Blood Purification, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan Conflict of Interests: Research Support: Chugai Pharmaceutical Co., Toray Industries, Torii Pharmaceutical Co. and Otsuka Pharmaceutical Co. Honoraria: Kyowa Hakko Kirin Co., Astellas Pharma, Asahi Kasei Pharma and NIPRO.
1
